Source: European Medicines Agency (EU) Revision Year: 2025 Publisher: UCB Pharma SA, Allée de la Recherche 60, B-1070 Brussels, Belgium
Xyrem 500 mg/mL oral solution.
Pharmaceutical Form |
---|
Oral solution. The oral solution is clear to slightly opalescent. |
Each mL of solution contains 500 mg of sodium oxybate.
For the full list of excipients, see section 6.1.
Active Ingredient |
---|
Sodium oxybate is a central nervous system depressant which reduces excessive daytime sleepiness and cataplexy in patients with narcolepsy and modifies sleep architecture reducing fragmented nighttime sleep. The precise mechanism by which sodium oxybate produces an effect is unknown, however sodium oxybate is thought to act by promoting slow (delta) wave sleep and consolidating night-time sleep. |
List of Excipients |
---|
Purified water |
180 mL solution in an amber oval 240 mL PET bottle which is delivered with a plastic/foil seal and closed with a child resistant closure composed of HDPE/polypropylene with a pulpboard inner liner.
Each carton contains one bottle, a press-in bottle adaptor, a graduated measuring device (polypropylene syringe), two polypropylene dosing cups and two HDPE child resistant screw closures.
UCB Pharma SA, Allée de la Recherche 60, B-1070 Brussels, Belgium
EU/1/05/312/001
Date for first authorisation: 13 October 2005
Date of latest renewal: 08 September 2015
Drug | Countries | |
---|---|---|
XYREM | Austria, Canada, Cyprus, Estonia, Spain, Finland, France, Croatia, Ireland, Italy, Lithuania, Netherlands, Poland, Turkey, United Kingdom, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.